portugal medical cannabis

Portugal grants the first and only authorization of medical cannabis products

Tilray, Inc. (NASDAQ: TLRY), which we have talked about in previous articles, is a world pioneer in cannabis research, cultivation, production and distribution. They company announced today that it has received the necessary market approvals and authorizations in accordance with Portuguese legislation to offer Tilray medicinal cannabis products in Portugal from its GMP certified EU facility in Cantanhede, Portugal. The marketing authorization was issued by Infarmed, the Portuguese National Authority for Medicines and Health Products, whose rigorous process for granting said consent is internationally recognized.

This is the first time that a full quality dossier has been requested and delivered to obtain market authorization in Europe for a medicinal cannabis product, and that process is now complete. The Infarmed approval confirms the quality and safety standards of Tilray’s Good Manufacturing Processes (GMP) certified production.

cannabis medical products

Portugal Regulations

In accordance with the Portuguese and Infarmed Medicinal Cannabis regulations, Tilray medicinal cannabis products are approved for the treatment of spasticity associated with multiple sclerosis or spinal cord injuries; nausea, vomiting (as a result of chemotherapy, radiation therapy, and combination HIV medication for hepatitis C); appetite stimulation in palliative care of patients undergoing cancer treatment or with HIV / AIDS; Tourette syndrome, epilepsy and treatment of severe seizure disorders in children; Therapeutic resistant glaucoma and chronic pain (associated with oncological or nervous system diseases, such as neuropathic pain injury caused by nerve damage, phantom limb pain, trigeminal neuralgia, or after herpes zoster).

Brendan Kennedy, CEO of Tilray, said: “Tilray is committed to quality and patient safety, and we look forward to significantly improving the quality of life for Portuguese patients through our medicinal cannabis products.” Sascha Mielcarek, Tilray’s Managing Director in Europe, says, “We are very proud of Infarmed’s market authorization, which confirms Tilray’s medical cannabis products live up to the highest national and international quality standards.”

It seems that from Canada Tilray is monopolizing the cannabis industry in a way, will they deliver what they promise?

portugal approves cannabis products

About the author

Leave a Reply

Your email address will not be published. Required fields are marked *

Click to Hide Advanced Floating Content
en_US
×